1 year ago

Work programme 2017


Medium-term objective

Medium-term objective MAWP initiative Activity description Timeframe Start End regulators on European assessment and output Ensure appropriate representation in relevant fora, to ensure convergence of standards Reduce time-to-patient of medicines through use of existing and new assessment approaches within existing legal frameworks, including through collaboration with international partners pharmaceutical quality through setting up a new cluster, with focus on innovation 4.2-8 Contribute to ICH activities on starting materials (ICH Q11 Q&As on starting materials) and lifecycle management (ICH Q12 on lifecycle management guideline) 1.3-4 Support activities stemming from Joint Action 3 / work package 4 by providing relevant information from regulatory assessment to HTA bodies for relative effectiveness assessments 2015 2017 2015 After 2017 Resources 2017 Financial resources (cost, thousand Euro) 35,312 Human resources (FTEs) 87 1.3. Post-authorisation activities Activity area Post-authorisation activities include all the activities performed by the Agency to maintain authorised medicines on the market and ensure that products on the EU market are kept up to date with scientific advances and in line with the needs of authorisation holders. Activities covered in this area include those described below. • Variations to marketing authorisations. These can be either minor (type IA or IB) or major (type II) changes to the product information and dossier with regard to the quality, safety and efficacy of the authorised product, including new or extended therapeutic indications and riskmanagement plans. • Applications for line extensions of marketing authorisations. These include fundamental changes to the medicinal product, such as changes to the active substance, changes to the strength, pharmaceutical form or route of administration of the medicinal product. • Maintenance activities. These include follow-up on certain obligations and measures that marketing-authorisation holders need to fulfil following the granting of marketing authorisations (MAs). These include reassessment and renewal of MAs, post-authorisation measures, transfers of MAs, and Article 61(3) notifications. Work programme 2017 EMA/583016/2016 Page 52/123

Drivers The workload of post-authorisation activities is expected to continue to increase, due to the organic increase in the number of centrally authorised products. To ensure its ability to handle these increasing volumes, the Agency will continue to simplify, rationalise and remove duplications when handling postauthorisation changes within the current regulatory framework. Product profiles change and evolve as new data on medicines are gathered and introduced after obtaining marketing authorisation. This raises the importance of maintaining a high quality of product information throughout the lifecycle of the medicine, and will be scrutinised to ensure product information is consistently up to date and meets the needs of the users. With optimised use of early access tools for the authorisation of medicines, it is important that postauthorisation data generation is closely followed up and new data are regularly evaluated. This covers both efficacy and safety data. Regulatory tools are in place for supporting appropriate decision-making during post-authorisation. Workload indicators Results Forecasts 2014 2015 2016 2017 Variations applications, of which: 6,006 5,999 6,204 6,270 Type-IA variations 2,969 2,864 3,019 2,773 Type-IB variations 1,886 1,980 2,000 2,228 Type-II variations 1,151 1,155 1,185 1,269 Line-extensions of marketing authorisations 16 14 25 15 PASS scientific advice through SAWP n/a 1 2 5 Number of consultations of SAGs / Ad-hoc expert groups in 6 12 the context of post-authorisation activities Renewal applications 107 62 Annual reassessment applications 25 26 Transfer of marketing authorisation applications 35 53 Article 61(3) applications 216 190 Post Authorisation Measure data submissions 1016 900 Plasma Master File Annual update and variation applications 19 17 Performance indicators Results Targets 2014 2015 2016 2017 Post-authorisation applications evaluated within the legal timeframes Average assessment time for variations that include extension of indication Average clock-stop for variations that include extension of indication % of submitted risk management plans peer reviewed by the Agency as part of the extension of indication and line 100% 99% 99% 99% 175 160 165 180 90 65.5 73 90 100% 100% 100% 100% Work programme 2017 EMA/583016/2016 Page 53/123

2017 Work Programme
MHRA powerpoint template - TOPRA
Work Programme 2011 - ERA - Europa
VMGN 11 - Veterinary Medicines Directorate - Defra
Work Programme 2013 - ECHA - Europa
IFAH-Europe annual report 2006 - Bundesverband für Tiergesundheit
How TOPRA in Spain will work - presentation
final programme - digital edition - seg/esg congress 2013
The 9th TOPRA Annual Symposium 2012 - Human Medicines
ANNUAL REPORT - Bundesverband für Tiergesundheit
Dr. Monica Vinhas de Souza - EHC
EFAMA Conference Programme
programme activities - European Consortium for Ocean Research ...
(CPD) Programme for Pharmaceutical Staff